Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

We recently compiled a list of the Jim Cramer Discusses These 10 Stocks & Comments On OpenAI’s Valuation. In this article, we ...

The projected fair value for Eli Lilly is US$1,419 based on 2 Stage Free Cash Flow to Equity The US$978 analyst price target ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to ...

Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli Lilly, directly. Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP ...

Get Wall Street's Hottest Chart Every Morning Medicare drug plans can now cover Eli Lilly And Co's LLY popular ... events restricting or blocking a person's airflow per hour of sleep, compared ...

Jan 13 (Reuters) - (This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has ... citing a person familiar with the matter. Lilly did not immediately respond to ...

Obstructive sleep apnea occurs when a person's upper airway becomes blocked ... The opportunity for Eli Lilly is significant, according to Leerink analyst David Risinger, who estimated in a ...